Jupiter Neurosciences buys exclusive U.S. rights to ALA-002

Jupiter Neurosciences said Tuesday it signed a definitive license agreement with PharmAla Biotech Holdings for perpetual exclusive U.S. rights to ALA-002, a patented non-racemic MDMA candidate with FDA Novel Chemical Entity status. The deal could be worth up to $100 million and gives Jupiter a second clinical-stage CNS asset alongside its Parkinson’s program.

Why it matters: - The deal moves Jupiter Neurosciences from a single-program company to a dual clinical-stage central nervous system developer. - ALA-002 adds an FDA-designated Novel Chemical Entity with potential regulatory protection and U.S. commercialization rights. - Jupiter is aiming to broaden its pipeline while keeping a path to future royalties and sales-based milestone payments.

What happened: - Jupiter Neurosciences entered a definitive license agreement with PharmAla Biotech Holdings for perpetual exclusive U.S. rights to ALA-002. - The company said the transaction has a potential value of up to $100 million, including milestone payments, excluding ongoing royalties. - Jupiter said the agreement expands its portfolio beyond its natural resveratrol program and Parkinson’s disease work.

The details: - Jupiter will pay $3.3 million upfront, including $1.5 million in cash and $1.8 million in JUNS common stock subject to a 120-day lock-up. - The deal includes a $3.3 million development milestone at Phase 3 first patient in. - Jupiter will owe a $20 million regulatory milestone if ALA-002 wins U.S. NDA approval. - Commercial milestones total $10 million, $30 million and $33.3 million at $333 million, $1 billion and $2 billion in cumulative U.S. net sales. - Jupiter will also pay a 3% royalty on net sales beginning after the third commercialization milestone. - ALA-002 is a patented, non-racemic MDMA formulation with FDA Novel Chemical Entity designation. - The designation provides enhanced regulatory protection and a five-year data exclusivity period upon approval. - Jupiter said ALA-002 was designed to improve cardiovascular safety and reduce abuse liability compared with racemic MDMA while preserving pro-social and therapeutic effects. - PharmAla’s MDMA supply is currently active in U.S. government-sponsored VA and DHA clinical trials. - Jupiter said PharmAla will continue manufacturing ALA-002 drug product under commercial terms to be negotiated. - PharmAla is a manufacturer and supplier of MDMA for clinical use with supply contracts on three continents, including the U.S. Veterans Affairs Administration and several Ivy League universities. - Jupiter’s lead program, JOTROL, is in a Phase IIa Parkinson’s disease trial. - Jupiter also commercializes Nugevia, a consumer longevity supplement. - The company said ALA-002 targets a U.S. psychedelic therapeutics market estimated at $3 billion in 2024 and $8 billion by 2030, citing Strategic Market Research.

Between the lines: - The agreement gives Jupiter exposure to psychedelic medicines at a time when U.S. policy appears more supportive of investigational treatments for serious mental illness. - Management is framing the deal as both a pipeline expansion and a balance-sheet strengthener through stock consideration and future milestones. - The company’s emphasis on two independent clinical programs suggests a push to diversify scientific and regulatory risk. - The executive order cited in the release could matter if federal agencies translate it into faster review paths or broader access programs, but those outcomes are not guaranteed.

What's next: - Jupiter said the immediate focus is clinical execution, capital allocation and advancing both programs toward milestones. - PharmAla will keep supplying ALA-002 for U.S. development under a commercial manufacturing arrangement still to be negotiated. - Future value will depend on clinical results, regulatory progress, financing and the pace of U.S. psychedelic drug policy implementation.

The bottom line: - Jupiter is paying for a bigger CNS story, with ALA-002 giving the company a second shot at value creation if the program advances through clinical and regulatory gates.